Daily Vitamin D increased HDAC2 and 25(OH)D levels in stable COPD patients without improving pulmonary function
Vitamin D supplement increased a protein marker in five COPD patients
This experimental study evaluated the effect of daily 5000 IU Vitamin D in five stable COPD patients over three months.
Daily Vitamin D supplements raised a protein marker in five COPD patients, but the study found no significant improvement in lung function a…
Low-dose theophylline shows modest FEV improvement but no exacerbation reduction in mild to moderate COPD
Can a low-dose pill help people with mild COPD breathe easier?
A 12-month randomized trial in 734 Chinese patients with mild to moderate COPD found oral low-dose theophylline (100 mg twice daily) produce…
A low-dose theophylline pill helped mild COPD patients exhale slightly better but did not reduce dangerous flare-ups during a year-long stud…
Genetic analysis links oral microbiota to COPD risk in East Asian population
Could the bacteria in your mouth affect your risk of COPD?
A genetic causal inference and bioinformatics analysis using East Asian GWAS data identified 48 oral microbial taxa associated with COPD ris…
A study in East Asian people links 48 types of mouth bacteria to COPD risk and identifies a gene and six existing drugs that might target it…
Prolonged prone positioning shows oxygenation benefit but inconclusive mortality effect in COVID-19 ARDS
Longer prone positioning may improve oxygen levels in COVID-19 ARDS patients
A meta-analysis of 996 COVID-19 patients with moderate-to-severe ARDS compared prolonged (>24 h/session) to standard (≤24 h/session) prone p…
Prolonged prone positioning for severe lung failure showed a trend toward lower death rates but increased pressure injury risks in COVID-19 …
SBRT shows early QoL advantage over CHRT in inoperable stage I NSCLC, but long-term scores converge
Which radiation therapy helps people with inoperable lung cancer feel better?
A phase 3 RCT of 233 patients with medically inoperable stage I NSCLC compared SBRT to CHRT.
For inoperable lung cancer, a newer radiation method offers early relief but conventional therapy catches up in overall health by two years.
FDA Approves Nintedanib Capsules (nintedanib esylate) for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILDs
FDA approves a new drug to treat two types of progressive, scarring lung diseases
The FDA has approved nintedanib capsules for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and for adults with chronic fi…
FDA approves new drug to treat two types of progressive, scarring lung diseases that make lungs stiff and hard to breathe.
FDA Approves Nintedanib Capsules (nintedanib esylate) for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILDs
FDA approves a new drug to treat two serious, scarring lung diseases in adults
The FDA has approved nintedanib capsules for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and for adults with chronic fi…
FDA approves new drug nintedanib to treat two serious, scarring lung diseases in adults with progressive conditions.
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma
Small study tests drug combination for rare, aggressive lung cancer
A phase II single-arm trial in 20 patients with recurrent/metastatic pulmonary sarcomatoid carcinoma evaluated durvalumab plus doxorubicin/i…
A rare lung cancer drug combo shrank tumors in 35% of patients, offering hope for those with this aggressive disease despite common side eff…
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer
Can adding two drugs after chemo help some lung cancer patients survive longer?
These prospective phase II single-arm studies assessed tislelizumab combined with sitravatinib or anlotinib as maintenance therapy in previo…
Adding tislelizumab plus sitravatinib or anlotinib after chemo kept some small-cell lung cancer patients cancer-free for 6.4 to 7.8 months.
Nonintubated anesthesia lowers postoperative NLR in thoracoscopic lung cancer resection compared to traditional intubation
Nonintubated anesthesia may lower inflammation markers after lung cancer surgery in a small study
This randomized controlled trial enrolled 58 patients undergoing video-assisted thoracoscopic lung surgery to compare nonintubated anesthesi…
Patients without breathing tubes during lung cancer surgery showed significantly lower inflammation levels 24 hours after the operation comp…
Systematic review of Traditional Chinese Exercise shows improved function and well-being in 2434 COPD patients
Traditional Chinese Exercise May Improve Function and Well-being in COPD Patients
This systematic review and meta-analysis of 32 randomized controlled trials involving 2,434 patients with COPD found that Traditional Chines…
Traditional Chinese Exercise helps COPD patients walk further, breathe easier, and feel less anxious or depressed, according to a review of …